Efficacy of S-1 in patients with capecitabine-resistant Breast Cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3827-3831

  Yamamoto, Daigo ^a,c   Iwase, S ^b   Yoshida, H ^a   Kuroda, Y ^b   Yamamoto, C ^c   Kitamura, K ^d   Odagiri, H ^e   Nagumo, Y ^f  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c Seiko Hospital   (Japan)

^d KYUSHU CENTRAL HOSPITAL   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f Breast Unit Nagumo Clinic   (Japan)

Author keywords

Capecitabine; Metastatic breast cancer; S 1

Indexed keywords

CAPECITABINE; PYRIMIDINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG COMBINATION; FLUOROURACIL; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; JAPAN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OXONIC ACID; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TEGAFUR; TREATMENT OUTCOME;

EID: 77958555564     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Shin HR, Boniol M, Joubert C, Hery C, Haukka J, Autier P, Nishino Y, Sobue T, Chen CJ, You SL, Ahn SH, Jung KW, Law SC, Mang O and Chia KS: Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci 101: 1141-1246, 2010.
2. Kawaguchi T, Iwase S, Takeuchi H, Ikeda A, Kuroda Y, Sakata N, Umeda M, Kobara K, Matsunaga T, Unezaki S and Nagumo Y: Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J 24: 9081, 2009.
3. Hortobagyi GN: Treatment of breast cancer N Engl J Med 339: 974-84, 1998.
4. Miwa M, Ura M, Nishida M Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropynmidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue Eur J Cancer 8: 1274-1281, 1998.
5. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768, 2001.
6. Walko CM and Lindley C: Capecitabine: a review. Clin Ther 27: 23-44, 2005.
7. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999. (Pubitemid 29075232)
8. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M and Lück HJ: Multicenter phase II study of oral capecitabine in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233, 2003.
9. Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z and Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536-542, 2004.
10. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V and Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
11. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S and Taguchi T: A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11: 194-202, 2004.
12. Hino M, Saeki T, Sato Y and Sano M: S-1 Cooperative Study Group, Breast Cancer Working Group. Late phase II study of S-1 in patients with taxane resistant breast cancer (ASCO Annual Meeting Proceedings). J Clin Oncol 22(14S): 745, 2004.
13. WHO Handbook for Reporting Results ol Cancer Treatment World Health Organization, Geneva, 1979.
14. Shien T, Shimizu C, Akashi-Tanaka S, Yonemori K, Kohno T, Hojo T, Ando M, Katsumata N, Kinoshita T and Fujiwara Y: Clinical wfficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol 38: 172-175, 2008.
15. Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T and Hatake K: Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine Breast Cancer 16: 126-131, 2009.
16. Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Ktitazato K Uchida J, Sugimoto Y, Nagayama S and Fukusima M: Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 25: 1531-1536, 2004.
17. Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H and Kouvaris J: Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 13: 1897-1922, 2008.